Cargando…

Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option

Atrial fibrillation (AF) is the most common sustained arrhythmia with a prevalence of up to 4% and an upwards trend due to demographic changes. It is associated with an increase in mortality and stroke incidences. While stroke risk can be significantly reduced through anticoagulant therapy, adequate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kraft, Manuel, Büscher, Antonius, Wiedmann, Felix, L’hoste, Yannick, Haefeli, Walter E., Frey, Norbert, Katus, Hugo A., Schmidt, Constanze
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058608/ https://www.ncbi.nlm.nih.gov/pubmed/33897427 http://dx.doi.org/10.3389/fphar.2021.638445

Ejemplares similares

Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium Channels
por: Ratte, Antonius, et al.
Publicado: (2019)

MicroRNAs Regulate TASK‐1 and Are Linked to Myocardial Dilatation in Atrial Fibrillation
por: Wiedmann, Felix, et al.
Publicado: (2022)

Prospective multicentric validation of a novel prediction model for paroxysmal atrial fibrillation
por: Schmidt, Constanze, et al.
Publicado: (2020)

Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue
por: Kraft, Manuel, et al.
Publicado: (2022)

The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal Model
por: Wiedmann, Felix, et al.
Publicado: (2021)

Pharmacologic TWIK‐Related Acid‐Sensitive K+ Channel (TASK‐1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model
por: Wiedmann, Felix, et al.
Publicado: (2020)

A Simple, Non-Invasive Score to Predict Paroxysmal Atrial Fibrillation
por: Kallenberger, Stefan M., et al.
Publicado: (2016)

N-glycosylation–dependent regulation of hK(2P)17.1 currents
por: Wiedmann, Felix, et al.
Publicado: (2019)

N-Glycosylation of TREK-1/hK(2P)2.1 Two-Pore-Domain Potassium (K(2P)) Channels
por: Wiedmann, Felix, et al.
Publicado: (2019)

The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation
por: Schmidt, Constanze, et al.
Publicado: (2011)

Two-Pore-Domain Potassium (K(2P)-) Channels: Cardiac Expression Patterns and Disease-Specific Remodelling Processes
por: Wiedmann, Felix, et al.
Publicado: (2021)

An instrument to measure atrial fibrillation knowledge in Chinese patients: validation of the Jessa Atrial fibrillation Knowledge Questionnaire
por: Chang, Sijie, et al.
Publicado: (2023)

Isoproterenol Increases Left Atrial Fibrosis and Susceptibility to Atrial Fibrillation by Inducing Atrial Ischemic Infarction in Rats
por: Ma, Shiyu, et al.
Publicado: (2020)

Honokiol Inhibits Atrial Metabolic Remodeling in Atrial Fibrillation Through Sirt3 Pathway
por: Liu, Guang Zhong, et al.
Publicado: (2022)

Calcium dysregulation in atrial fibrillation: the role of CaMKII
por: Heijman, Jordi, et al.
Publicado: (2014)

The Antimalarial Chloroquine Reduces the Burden of Persistent Atrial Fibrillation
por: Tobón, Catalina, et al.
Publicado: (2019)

Small Conductance Ca(2 +)-Activated K(+) (SK) Channel mRNA Expression in Human Atrial and Ventricular Tissue: Comparison Between Donor, Atrial Fibrillation and Heart Failure Tissue
por: Darkow, Elisa, et al.
Publicado: (2021)

Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
por: Suo, Ya, et al.
Publicado: (2019)

Case report of an S-ICD implantation for secondary prevention in a patient with complex congenital heart disease, dextrocardia, and situs solitus
por: Wiedmann, Felix, et al.
Publicado: (2022)

Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity
por: Hansen, Carolina Malta, et al.
Publicado: (2012)

Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms
por: Yang, Xinyu, et al.
Publicado: (2018)

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
por: Lin, Shin-Yi, et al.
Publicado: (2021)

Peptide Inhibitors of Kv1.5: An Option for the Treatment of Atrial Fibrillation
por: Borrego, Jesús, et al.
Publicado: (2021)

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
por: Lai, Kuan-Cheng, et al.
Publicado: (2018)

Altered atrial cytosolic calcium handling contributes to the development of postoperative atrial fibrillation
por: Fakuade, Funsho E, et al.
Publicado: (2020)

Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation
por: Schweizer, Patrick A, et al.
Publicado: (2011)

Pharmacological Inhibition of Serine Proteases to Reduce Cardiac Inflammation and Fibrosis in Atrial Fibrillation
por: Coppini, Raffaele, et al.
Publicado: (2019)

Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation
por: Perreault, Sylvie, et al.
Publicado: (2022)

Low Quality of Warfarin Therapy is Associated With Female Gender but Not With Polypharmacy in Patients With Atrial Fibrillation
por: Takamoto, Kojiro, et al.
Publicado: (2021)

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
por: Li, Xiaoye, et al.
Publicado: (2021)

Effects of I(Kur) blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation
por: Loose, Simone, et al.
Publicado: (2014)

Hydrogen Sulfide Ameliorates Angiotensin II-Induced Atrial Fibrosis Progression to Atrial Fibrillation Through Inhibition of the Warburg Effect and Endoplasmic Reticulum Stress
por: Hu, Heng-Jing, et al.
Publicado: (2021)

Pharmacologic Management of Atrial Fibrillation: Established and Emerging Options
por: Kalus, James S.
Publicado: (2009)

Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms
por: Geng, Meng, et al.
Publicado: (2020)

The Acetylcholine-Activated Potassium Current Inhibitor XAF-1407 Terminates Persistent Atrial Fibrillation in Goats
por: Sobota, Vladimír, et al.
Publicado: (2021)

Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2021)

Pinocembrin ameliorates atrial fibrillation susceptibility in rats with anxiety disorder induced by empty bottle stimulation
por: Ran, Qian, et al.
Publicado: (2022)

LncRNA Nuclear-Enriched Abundant Transcript 1 Regulates Atrial Fibrosis via the miR-320/NPAS2 Axis in Atrial Fibrillation
por: Dai, Huangdong, et al.
Publicado: (2021)

Regulation of CaMKII signaling in cardiovascular disease
por: Mollova, Mariya Y., et al.
Publicado: (2015)

Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Grymonprez, Maxim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_747shdkudhg9kosoio11duc4td